ASP Isotopes Inc Dossier
Qualitative Analysis
Business overview
ASP Isotopes Inc. (NASDAQ: ASPI) is an advanced materials company dedicated to developing a highly differentiated isotope enrichment platform. The company leverages its proprietary Aerodynamic Separation Process (ASP technology) and Quantum Enrichment (QE technology) to produce scarce, high-value isotopes. These critical materials serve high-growth end markets including nuclear medicine (e.g., Carbon-14, Ytterbium-176), next-generation semiconductors and quantum computing (Silicon-28), and advanced nuclear energy (High-Assay Low-Enriched Uranium, or HALEU, and Lithium-6). Headquartered in Dallas, Texas, the company centers its manufacturing buildout in South Africa to access specialized enrichment expertise and operate dedicated plants with lower capital intensity and modularity compared to traditional gas centrifuge methods.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Restarting and scaling the first 18 stages of the Silicon-28 enrichment facility in Pretoria, South Africa, following engineering enhancements to non-core components.
Expected impact: Fulfills three commercial contracts with U.S.-based customers, establishing a stable semiconductor and quantum computing supply franchise.
Developing high-assay low-enriched uranium (HALEU) and Lithium-6 enrichment capabilities through the Quantum Leap Energy (QLE) subsidiary, supported by a supply framework with TerraPower.
Expected impact: Positions the company as a key Western supplier of next-generation nuclear fuels for Small Modular Reactors (SMRs).
Planning the separation and independent public listing of the QLE subsidiary to address its distinct capital needs and customer base.
Expected impact: Optimizes corporate structure, isolates uranium-related regulatory declarations, and allows independent capital raising.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Integrates ASP Isotopes' advanced enrichment technologies with Renergen's established helium and natural gas operations at the Virginia Gas Project, creating a vertically integrated global provider of critical materials.
Financial impact: Began contributing LNG and helium revenues in 1Q 2026; expected to be highly accretive to revenue and cash flow, targeting over $300 million in EBITDA by 2030.
Strategic Partnerships
High; secures a 10-year HALEU supply framework and provides a $22.0 million conditional loan to support advanced nuclear fuel development.
Terms: $22.0 million conditional multiple advance term loan (inclusive of a 10% original issue discount on each disbursement, resulting in up to $20.0 million in aggregate disbursements) carrying a fixed interest rate of 10% per annum and maturing on May 16, 2032.
High; establishes a joint venture to collaborate on the research, development, and construction of an advanced nuclear fuel enrichment facility (HALEU) and a stable isotope production plant at the HyperGrid campus in Texas.
Terms: Undisclosed joint equity contribution.